Is Exelixis (EXEL) Undervalued On Cabozantinib Patent Risk And Launch Execution?

Recent discussion around Exelixis (EXEL) has focused on the limited remaining patent life of cabozantinib, with investors now weighing execution risk on future oncology launches and reassessing the stock’s valuation.

At a share price of US$59.86, Exelixis has seen strong momentum build, with a 37.36% year to date share price return and a 56.91% total shareholder return over the past year. The 180.24% three year total shareholder return highlights how the cabozantinib story and the evolving execution risk debate have shaped both recent gains and the longer term rerating.

Compare Exelixis with a curated group of oncology-focused peers by screening for 28 high quality undervalued stocks that are also wrestling with patent cliffs and pipeline execution risk.

Exelixis now trades above the average analyst target, yet sits at a steep discount to some intrinsic value estimates. Where does fair value really land after this sharp rerating?

Most Popular Narrative: 9% Undervalued

Against Exelixis' last close at $59.86, the most followed narrative pegs fair value at $66.00, framing the recent rally as only part of the story rather than the finish line.

The expansion of Exelixis’ GI focused commercial platform and use of more granular utilization data for colorectal and kidney cancer gives zanzalintinib and future assets a ready made sales infrastructure that can support incremental revenue without proportional selling expense growth, which can help operating margins.

The breadth of seven ongoing or imminent pivotal zanzalintinib trials across colorectal cancer, non clear cell RCC, neuroendocrine tumors, meningioma and other GU or GI tumors creates scope for multiple indications to layer on over time, which can shift Exelixis’ revenue mix away from a single compound and affect earnings resilience.

See why 11 investors see Exelixis as 9% undervalued.

Result: Fair Value of $66.00 (UNDERVALUED)

Still, the Exelixis story hinges on cabozantinib concentration and a clean zanzalintinib rollout. Any stumble on guidance, approvals or legal outcomes could quickly challenge this 9% undervalued view.

Find out about the key risks to this Exelixis narrative.

Next Steps

With sentiment leaning optimistic on Exelixis, the real edge comes from testing that mood against hard numbers and your own risk comfort. Move past headlines by reviewing the 4 key rewards.

Looking for more investment ideas beyond Exelixis?

Do not stop with Exelixis. Put fresh ideas on your radar by using the Simply Wall Street Screener to spot opportunities that match your style before others do.

• Target resilience by filtering for companies with strong finances and low leverage by using our list of solid balance sheet and fundamentals (25 results).
• Hunt for quality at a discount by focusing on businesses that look attractively priced through the 28 high quality undervalued stocks.
• Lock in income potential by reviewing companies with robust payout profiles using the 8 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com